ARDS

Acute respiratory distress syndrome (ARDS) is a rapidly progressing condition that affects critically ill people. The major complication of ARDS is fluid leaking into the lungs, which makes breathing difficult or impossible. Shortness of breath, cough, and fever are among ARDS symptoms; in certain cases, high heart...

Despite decades of research, treatment options are limited in the ARDS market. There are only a few treatments available in the ARDS market. The mainstay of management remains supportive care with mechanical ventilation. Other ARDS treatment options for patients include supplemental oxygen, prone positioning, the u...

The acute respiratory distress syndrome (ARDS) prevalence is increasing every year; it is estimated that in the United States alone, about 190K Americans are diagnosed with ARDS each year. Prior to the COVID-19 global pandemic, more than 700K individuals in the US and 2 million cases globally developed ARDS from tr...

Acute respiratory distress syndrome (ARDS) is a serious lung condition that is associated with a substantial rate of morbidity and mortality. It is a common cause of respiratory failure in infants and critically ill patients.  Characterized by the acute onset of noncardiogenic pulmonary oedema, hypoxaemia, ARD...

Alnylam Pharmaceuticals has released the Phase III results of the clinical trial ILLUMINATE-A evaluating lumasiran for Primary Hyperoxaluria Type 1 Primary Hyperoxaluria Type 1 (PH1) is a rare disorder that affects kidneys due to an excess buildup of oxalate, which in normal cases is filtered through the kidneys...

The Novel Coronavirus since its outbreak in Wuhan China in November-2019 has infected around 1,848,439 people with 117,217 confirmed deaths in 213 countries, till date.  Countries around the world are working tirelessly to tackle the current situation. Local Governments in order to reduce the pace of corona...

Eli Lilly has announced to begin clinical trials of rheumatoid arthritis drug Olumiant to treat COVID-19 patients.  The company plans to explore the anti-inflammatory responses that were witnessed in rheumatoid arthritis patients, and how the drug – Olumiant – an oral JAK1/JAK2 inhibitor – might help in cur...